Scholars Central

Conference abstractPublished 2 Nov 2017

Ex vivo-expanded allogeneic NK cells for treatment of refractory and recurrent lymphoma and solid tumors

Authors: Yu-Kyeong Hwang

Cell Therapy Research Center, Green Cross Lab Cell Corp., South Korea

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Allogeneic NK cells have been used for their activity for hematologic cancer by hematopoietic stem cell transplantation. During the last decades, anti-cancer activity of ex vivoexpanded NK cells were demonstrated in several studies, both in vitro and in vivo. Previously, ex vivo expanded allogeneic NK cells (MG4101) from healthy unrelated donor showed potent anti-tumor activity with tolerable toxicity profiles in several xenograft models. From healthy donor’s peripheral blood mononuclear cells (PBMCs), NK cells expanded under good manufacturing practice (GMP) conditions. NK cells selectively killed cancer cells without demonstrating cytotoxicity against allogeneic non-tumor cells in co-culture assays, and show the anti-tumor activity in various cancer model including lymphoma, ovarian cancer, hepatocellular carcinoma, neuroblastoma and glioblastoma. Phase I clinical trial had been conducted in 18-advanced and refractory cancer patients with various solid tumor and lymphoma by dose-escalating infusing. No adverse effects were reported after, and changes of immune cell population and cytokine/chemokine levels were shown by NK cell infusion. Therefore, allogeneic NK cell treatment without T cell contamination is feasible for cancer patients, and good clinical outcome is expected if it is used with adequate preconditioning regimen. For more additive efficacies, two more clinical trials have been conducted in patient’s solid tumor after HSCT and in HCC patients after curative resection. Both study showed its safety and delayed progress free survival (PFS) and recurrent free survival (TTP), respectively. Based on this NK cell manufacturing process, new genetically modifying technology like chimeric antigen receptor (CAR) technology can be emerged. NK cell is one of option to solve the problem in adverse effect in CAR-T therapy. In cooperation with many of advanced technology, NK cell therapy can be a new modality for the cancer treatment as an off-the-shelf product.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectHaematology
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Yu-Kyeong Hwang”